Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2

Circulation

Volumn 97, Issue 12, 1998, Pages 1150-1156

  Barron, Hal V ^a,e   Bowlby, Laura J ^a   Breen, Tim ^a   Rogers, William J ^e   Canto, John G ^e   Zhang, Yuan ^b   Tiefenbrunn, Alan J ^c   Weaver, W Douglas ^d  

^a GENENTECH INC   (United States)

^b Southcreek Park   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e NONE

Author keywords

Angioplasty; Myocardial infarction; Prognosis; Reperfusion; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT INDICATION;

EID: 0032584114     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.12.1150     Document Type: Article

References (25)

1. Fibrinolytic Therapy Trialists (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative in overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
2. Grines CL, Browne KF, Marco J. Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B. Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S. O'Niel WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardiol Infarction Study Group. N Engl J Med 1993;328:673-679
3. Mitchels KB, Yusuf S. Does PTCA in acute myocardiol infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation. 1995;91:476-485.
4. Zijlstra F, de Boer MJ, Hoorntje JC, Rentes S, Reiber JH, Suryapranata H. A comparison of intermediate coronary angioplasty with intravenous streptokinase in acute myocardiol infarction. N Engl J Med. 1993;328: 680-684.
5. McGovern PG, Pankow, JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H. Luepker RV, for the Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med. 1996;334:884-890.
6. Ryan, TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO. Smith EEI. Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
7. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolyis for acute myocardiol infarction. Lancet. 1993; 342:891-894.
8. Phillips BG, Yim JM, Brown EJ Jr, Bittar N, Hoon TJ, Celestin C. Masses PH, Battman JL. Pharmacologic profile of survivorss of acute imocardial miarction at United States academic hospitals. Am Heart J. 1996;131:872-878.
9. Every NR, Larson EB, Litwin PE, Maynard C. Fihn SD. Eisenberg MS, Hallstrom AP, Martin JS, Weaver WD, for the Myocardial infarction Triage and Intervention Project Investigators. The association between on-site cardiac catheterization facilities and the use of coronary angiography after acute myocardial infarction. N Engl J Med. 1993;329: 546-551.
10. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet. 1996;347: 1203-1207.
11. Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, O'Niel WW, Schreiher TL. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991;115:173-177.
12. Muller DW, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Imtern Med. 1990;113:949-960.
13. French JK, Williams BF Hart HH, Wyatt S, Poole JE, Ingram C, Ellis CJ. Williams MG, White HD Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ. 1996;312: 1637-1641.
14. McLaghlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, McLaughlin B, Morris N, Cheng SC, Hauptman PJ, Antman E, Casey L, Asinger R, Gobel F. Adherance to national guidelines for drug treatment of suspected acute myocardiol infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
15. Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased use of thrombolytic therapy. Arch Intern Med. 1994;154: 1605-1609.
16. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.
17. Tobin JN, Wussertheil-Smoller S, Wexler JP, Steingart RM, Budner N, Lense L, Wachspress J. Sex bias in considering coronary bypass surgery. Ann Intern Med. 1987;107:19-25.
18. Fiebach NH, Viscoli CM, Horwitz RI. Differences between women and men in survival after myocardial infarction: biology or methodology? JAMA. 1990;263:1092-1096.
19. Tofler GH, Stone PH, Muller JE, Willich SN, Davis VG, Poole WK, Strauss HW, Willerson JT, Jaffe AS, Robertson T, Passamani E, Braunwald E. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particulary black women. J Am Coll Cardiol. 1987;9:473-482.
20. Ayanian JZ, Epstein AM. Difference in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. 1991;325:221-225.
21. Steiengart RM, Packer M, Hamm P, Coglianese ME, Gersh B, Geltman EM, Sollano J, Katz S, Moye L, Basta LL, Lewis SJ, Gottlieb SS, Bernstein V, McEwan P, Jacobson K, Brown EJ, Kurkin ML, Kantrowitz NE, Pfeffer MA, for the Survival and Ventricular Enlargement Investigators. Sex differences in the management of coronary artery disease. N Engl J Med. 1991;325:226-230.
22. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ. Regional variation across the United States in the management of acute myocardial infarction: GUSTO-1 Inves-tigators - Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333:565-572.
23. Cox DA, Rogers, WJ, Aguirre FV, Forman S, Solomon R, Zaret BL. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. Am J Cardial. 1994;73:729-736.
24. Vorchheimer DA, Baruch L, Kukin LM, Pieper KS, Granger CB, Topol EJ, Califf RM. Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome?' J Am Coll Cardiol. 1996;27:389A. Abstract.
25. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the Crated States (1990 to 1993): obsersations from the National Registry of Myocardial Infarction. Circulation. 1994;90: 2103-2114.